Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Files An 8-K Results of Operations and Financial Condition
Item 2.02
On January 6, 2019, Accelerate Diagnostics, Inc. issued a press release announcing certain preliminary financial results for the quarter ending December 31, 2018 and full-year 2018. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference in its entirety.
In accordance with General Instruction B.2 for Form 8-K, the information in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
| Item 9.01 | Financial Statements and Exhibits. |
(d)Exhibits.
| Exhibit | |
| Number | Description |
| 99.1 | Press Release, dated January 6, 2019 |
Accelerate Diagnostics, Inc Exhibit
EX-99.1 2 tv510482_ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 Accelerate Diagnostics announces preliminary 2018 fourth quarter and full-year financial results Added 117 commercially contracted U.S. instruments in Q4,…
To view the full exhibit click here
About Accelerate Diagnostics, Inc. (NASDAQ:AXDX)
Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions that improve patient outcomes and lower healthcare costs through the diagnosis of serious infections. The Company’s technology platform is built to address these challenges by delivering testing of infectious pathogens in various patient sample types. The Company is focused on the development of a rapid diagnostic platform, the Accelerate ID/AST System (ID/AST System or Accelerate ID/AST System), intended for the diagnosis of infectious pathogens. The ID/AST System utilizes genotypic technology to identify (ID) infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. The ID/AST System features walk-away automation and consists of a fixed instrument and single-use test kit.
